The US Cancer Institute is currently conducting a study on ivermectin's potential to combat cancer cells, marking a significant shift in the medical community's approach to this controversial drug. This decision has sparked intense debate among scientists, with some expressing shock and concern over the allocation of resources for preclinical research based on non-scientific ideas. But here's where it gets controversial: the study is being led by Anthony Letai, a physician appointed by the Trump administration, who has emphasized the need to take ivermectin seriously due to its growing popularity and perceived benefits. Despite the lack of new evidence, the National Cancer Institute is exploring ivermectin's effectiveness against cancer, citing the need to investigate promising leads. However, this approach has raised eyebrows among career scientists, who question the wisdom of investing taxpayer funds in a drug with limited evidence of safety and efficacy in cancer treatment. The FDA has approved ivermectin for specific human and animal uses, but has also warned against large doses that can be dangerous. The study's funding and potential impact on public health remain uncertain, as the National Cancer Institute has not disclosed the amount spent or the involvement of external institutions. This development highlights the ongoing tension between scientific rigor and the pursuit of innovative treatments, leaving many to wonder if the potential benefits outweigh the risks.
